Hope for Muscarinics: A New Option for Schizophrenia
Later this month, the FDA will vote on KarXT, a novel muscarinic acetylcholine receptor agonist.
Carmen Kosicek, MSN, PMHNP-BC, discusses the muscarinics. Here's a brief overview of what you need to know before the FDA votes on KarXT. Its novel mechanism of action could be the next breakthrough in the treatment of schizophrenia.
Kosicek is the program chair of the upcoming Real Psychiatry meeting, an immersive conference designed by psychiatric APPs for psychiatric APPs, that will take place on January 17–18, 2025, in Scottsdale, AZ.
The conference features expert presentations and panel discussions that showcase best practices for managing a multitude of psychiatric diagnoses, including major depressive disorder, substance use disorders, bipolar, schizophrenia, ADHD, and more.
Ms Kosicek is the CEO, Founder, and and a practicing PMHNP at Visionary Psychiatry—a hybrid, onsite/remote, psychiatric specialty of medication management providers offering services throughout Oregon.
